High-Potency APIs and Biologic Manufacturing Present Strong Growth Opportunities for Contract Manufacturing Organizations

LONDON, Sept. 28, 2016 /PRNewswire/ -- The global contract manufacturing organization (CMO) market is transforming to leverage changes in the pharmaceutical industry. Pharmaceutical companies continue to gain financially and overcome marketplace challenges, source innovative ideas, processes, skills and technologies by outsourcing to CMOs. However, the "vendor approach" model is not generating optimal results for the CMO industry. Expanding services into early stage drug development, complex technology transfer contracts, and flexible capacity supply agreements will enable CMOs to create a "transformational partnership approach" model with pharmaceutical companies.

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market is part of Frost & Sullivan's Life Sciences Growth Partnership Service program, which also includes insights on contract research, biosimilars, orphan drugs, generics, immuno-oncology therapeutics, regenerative medicines, pharmaceutical regulatory landscape and market access.

For complimentary access to more information on this research, please visit: http://frost.ly/tk.

"In addition to cost benefits and the freedom to focus on core competencies, outsourcing will allow pharma companies to optimize manufacturing capacity utilization rates as blockbuster drugs come off patent," said Transformational Health Program Manager Unmesh Lal. "Several CMOs are already repositioning themselves from low- to high-margin formulation manufacturers in order to attract crucial upstream and downstream biopharma processing operations."

CMOs need to enhance their technical capabilities and amend business models to access the huge market. Along with early-stage of drugs, CMOs must explore opportunities in virtual biotech, out-licensing, and risk sharing business models with clients. Expanding services into biologics and biosimilars manufacturing as well as high-potency active pharmaceutical ingredient (HPAPIs) will present enormous growth opportunities.

The challenges lie in the reservations of biopharma companies regarding breach of patent and IP information, concerns regarding the loss of manufacturing control, the stickiness of the CMO business, and the existing, expanding in-house manufacturing capacity of big pharma. Further, personalized therapy products outsourcing is not as attractive for large-scale CMOs.

"To strengthen their position and integrate into the value-chain of pharmaceutical companies, CMOs are turning into one-stop-shop contract development and manufacturing organizations (CDMOs) to provide value-added services," noted Lal. "Increasingly focusing on pre-clinical development services, CDMOs can then transition from clinical services to offering commercial manufacturing."

The global CMO market will also see more consolidation as participants look to inorganic growth strategies to offer integrated solutions to customers. For instance, Patheon, Catalent and AMRI have acquired IRIX Pharmaceuticals, Pharmatek and Euticals respectively. They have been aggressive in expanding their product/services/capabilities through strategic alliances. Similarly, Aenova maintained its market position after the acquisition of Haupt Pharma AG and by selling its Temmler business in 2015. Both Fareva and Famar have successfully adopted an integration strategy of acquiring manufacturing facilities in Europe from large pharmaceutical companies.

Therefore, the emerging CDMO business model, transformation in the pharmaceutical ecosystem, disruptive drug development and manufacturing technologies, and major growth opportunities in high potency and biopharmaceuticals manufacturing are driving differentiation strategies for the long-term profitability of CMOs.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market
P8D4-52

Contact:
Jana Schöneborn
Corporate Communications – Europe
P: +49 (0)69 77033 43
E: [email protected]

http://www.frost.com
twitter: @FS_Healthcare
LinkedIn: Transform Health

Photo - http://photos.prnewswire.com/prnh/20160928/412732

SOURCE Frost & Sullivan